Sucampo reports promising results from Phase IIa lumbar spinal stenosis study

Sucampo Pharmaceuticals has reported positive results from its Phase IIa study evaluating safety and efficacy of an intravenously (IV) administered compound of the company's ion channel activator programme in patients with lumbar spinal stenosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news